These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 19883301

  • 21. Autologous stem cell transplant in a patient with Down syndrome and relapsed Hodgkin lymphoma.
    Eckrich MJ, Domm J, Ho R, Whitlock JA, Frangoul H.
    Pediatr Blood Cancer; 2009 Dec 15; 53(7):1327-8. PubMed ID: 19760777
    [Abstract] [Full Text] [Related]

  • 22. [Primary refractory and relapsed Hodgkin lymphoma with unfavorable prognosis].
    Tarasenkova AA, Filatova LV, Gershanovich ML, Semiglazova TIu.
    Vopr Onkol; 2012 Dec 15; 58(1):101-9. PubMed ID: 22629838
    [Abstract] [Full Text] [Related]

  • 23. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma.
    Bauer K, Skoetz N, Monsef I, Engert A, Brillant C.
    Cochrane Database Syst Rev; 2011 Aug 10; (8):CD007941. PubMed ID: 21833963
    [Abstract] [Full Text] [Related]

  • 24. Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma.
    Fizesan M, Boin C, Aujoulat O, Newinger G, Ghergus D, Watier H, Lustig H, Ojeda-Uribe M.
    J Oncol Pharm Pract; 2016 Feb 10; 22(1):188-92. PubMed ID: 25586990
    [No Abstract] [Full Text] [Related]

  • 25. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.
    Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A, Borchmann P.
    Lancet Oncol; 2013 Sep 10; 14(10):943-52. PubMed ID: 23948348
    [Abstract] [Full Text] [Related]

  • 26. Chemotherapy for Hodgkin's disease.
    Ekert H.
    N Engl J Med; 2003 Sep 18; 349(12):1186-7; author reply 1186-7. PubMed ID: 13679536
    [No Abstract] [Full Text] [Related]

  • 27. [Treatment of advanced Hodgkin lymphoma].
    Kreissl S, Borchmann P.
    Dtsch Med Wochenschr; 2013 Jun 18; 138(23):1212-4. PubMed ID: 23720173
    [No Abstract] [Full Text] [Related]

  • 28. Hodgkin's disease--clinical trials and travails.
    DeVita VT.
    N Engl J Med; 2003 Jun 12; 348(24):2375-6. PubMed ID: 12802021
    [No Abstract] [Full Text] [Related]

  • 29. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG, Schoppe WD, Fuchs R, Pflüger KH, Loeffler M, Diehl V.
    Cancer Treat Rep; 1987 Dec 12; 71(12):1203-7. PubMed ID: 2446751
    [Abstract] [Full Text] [Related]

  • 30. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
    Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A.
    J Clin Oncol; 2011 Nov 10; 29(32):4234-42. PubMed ID: 21990399
    [Abstract] [Full Text] [Related]

  • 31. ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial.
    Fermé C, Thomas J, Brice P, Casasnovas O, Vranovsky A, Bologna S, Lugtenburg PJ, Bouabdallah R, Carde P, Sebban C, Eghbali H, Salles G, van Imhoff GW, Thyss A, Noordijk EM, Reman O, Lybeert MLM, Janvier M, Spina M, Audhuy B, Raemaekers JMM, Delarue R, Anglaret B, de Weerdt O, Marjanovic Z, Tersteeg RJHA, de Jong D, Brière J, Henry-Amar M, European Organisation for Research and Treatment of Cancer Lymphoma Group, and, Groupe d'Étude des Lymphomes de l'Adulte.
    Eur J Cancer; 2017 Aug 10; 81():45-55. PubMed ID: 28601705
    [Abstract] [Full Text] [Related]

  • 32. Bleomycin-Induced Flagellate Dermatitis.
    Turan Erkek E, Karaali CN, Yılmaz G, Gültürk E.
    Turk J Haematol; 2019 May 03; 36(2):138-140. PubMed ID: 30600679
    [No Abstract] [Full Text] [Related]

  • 33. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group.
    Bredenfeld H, Franklin J, Nogova L, Josting A, Fries S, Mailänder V, Oertel J, Diehl V, Engert A, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2004 Jun 15; 22(12):2424-9. PubMed ID: 15136597
    [Abstract] [Full Text] [Related]

  • 34. Vanishing bile duct-like syndrome in a patient with Hodgkin lymphoma - pathological development and restitution.
    Hallén K, Sangfelt P, Nilsson T, Nordgren H, Wanders A, Molin D.
    Acta Oncol; 2014 Sep 15; 53(9):1271-5. PubMed ID: 24697745
    [No Abstract] [Full Text] [Related]

  • 35. Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma.
    Cao H, Yamamoto K, Yang LX, Weber R.
    Anticancer Res; 2013 Sep 15; 33(9):3879-85. PubMed ID: 24023323
    [Abstract] [Full Text] [Related]

  • 36. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
    Shankar A, Hayward J, Kirkwood A, McCarthy K, Hewitt M, Morland B, Daw S.
    Br J Haematol; 2014 May 15; 165(4):534-44. PubMed ID: 24754633
    [Abstract] [Full Text] [Related]

  • 37. Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy.
    Bröckelmann PJ, Müller H, Guhl T, Behringer K, Fuchs M, Moccia AA, Rank A, Soekler M, Vieler T, Pabst T, Baues C, von Tresckow B, Borchmann P, Engert A.
    J Clin Oncol; 2021 Jan 10; 39(2):107-115. PubMed ID: 33058716
    [Abstract] [Full Text] [Related]

  • 38. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A.
    J Clin Oncol; 2010 Sep 20; 28(27):4199-206. PubMed ID: 20713848
    [Abstract] [Full Text] [Related]

  • 39. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
    Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Müller M, Fätkenheuer G, Seidel E, Nickelsen M, Wolf T, Rieke A, Schürmann D, Schmidmaier R, Planker M, Alt J, Mosthaf F, Engert A, Arasteh K, Hoffmann C.
    J Clin Oncol; 2012 Nov 20; 30(33):4117-23. PubMed ID: 23045592
    [Abstract] [Full Text] [Related]

  • 40. [Treating Hodgkin's disease: for whom the more means better?].
    Illés A.
    Magy Onkol; 2004 Nov 20; 48(2):157-61. PubMed ID: 15351812
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.